UNDBIO signs MOU to build insulin manufacturing facility in U.S.

Yoo Joo-yeon and Minu Kim 입력 2022. 6. 23. 13:51
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Korean insulin developer UNDBIO Inc. has signed a memorandum of understanding to build an insulin manufacturing and research facility in West Virginia, United States to speed up its forays into overseas markets with more affordable insulin and insulin analog products.

An MOU signing ceremony was attended by UNDBIO Chairman Jun Yong-soo and West Virginia Department of Economic Development Cabinet Secretary Mitch Carmichael, according to the company on Wednesday.

UNDBIO said it will complete its pilot facility to be built at the West Virginia University Research Park in 2023 and manufacture drugs for human clinical trials in 2024.

More than 50 million people are affected by diabetes in the U.S. with 16 percent of adults in West Virginia, but access to injectable insulin is challenging due to high prices in the country, said a company official.

“We are ready to cooperate as much as possible for the construction of UNDBIO’s insulin plant,” said Senator Shelley Moore Capito, R-W.Va., who applauded the MOU, adding “the plant will bring more than 1,000 new jobs to the area over the next few years.”

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?